BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32602003)

  • 21. Are all RAS mutations the same? Coexisting KRAS and NRAS mutations in a caecal adenocarcinoma and contiguous tubulovillous adenoma.
    Vagaja NN; Parry J; McCallum D; Thomas MA; Bentel JM
    J Clin Pathol; 2015 Aug; 68(8):657-60. PubMed ID: 25926041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [KRAS gene mutation in colorectal cancer].
    Roa I; Sánchez T; Majlis A; Schalper K
    Rev Med Chil; 2013 Sep; 141(9):1166-72. PubMed ID: 24522420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan-cancer setting.
    Mardinian K; Okamura R; Kato S; Kurzrock R
    Int J Cancer; 2020 Jan; 146(2):566-576. PubMed ID: 31199507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
    Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
    J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRAS and BRAF mutations in Serbian patients with colorectal cancer.
    Jakovljevic K; Malisic E; Cavic M; Krivokuca A; Dobricic J; Jankovic R
    J BUON; 2012; 17(3):575-80. PubMed ID: 23033302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C.
    Cannataro VL; Gaffney SG; Stender C; Zhao ZM; Philips M; Greenstein AE; Townsend JP
    Oncogene; 2018 May; 37(18):2444-2455. PubMed ID: 29453361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the RAS-dependent chemoresistance: The Warburg connection.
    Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
    Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
    Neumann J; Zeindl-Eberhart E; Kirchner T; Jung A
    Pathol Res Pract; 2009; 205(12):858-62. PubMed ID: 19679400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
    Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
    BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
    Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
    JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NGS-based oncogenic mutations analysis in advanced colorectal cancer patients improves targeted therapy prediction.
    Li W; Qiu T; Guo L; Ying J; Zhou A
    Pathol Res Pract; 2019 Mar; 215(3):483-489. PubMed ID: 30611619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Correlation between KRAS mutations and clinicopathologic features in colorectal carcinomas].
    Gao J; Zhang J; Lu T; Li XY; Jia N; Liang ZY
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):595-8. PubMed ID: 23157826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [KRAS gene somatic mutations in Chilean patients with colorectal cancer].
    Hurtado C; Encina G; Wielandt AM; Zárate AJ; Castro M; Carrillo K; Kronberg U; López-Köstner F
    Rev Med Chil; 2014 Nov; 142(11):1407-14. PubMed ID: 25694286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High Frequency of KRAS Codon 146 and FBXW7 Mutations in Thai Patients with Stage II-III Colon Cancer.
    Korphaisarn K; Pongpaibul A; Roothumnong E; Pongsuktavorn K; Thamlikitkul L; Anekpuritanang T; Poungvarin N; Thongnoppakhun W; Pithukpakorn M
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2319-2326. PubMed ID: 31450901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
    Suh JH; Johnson A; Albacker L; Wang K; Chmielecki J; Frampton G; Gay L; Elvin JA; Vergilio JA; Ali S; Miller VA; Stephens PJ; Ross JS
    Oncologist; 2016 Jun; 21(6):684-91. PubMed ID: 27151654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients.
    Hamzehzadeh L; Khadangi F; Ghayoor Karimiani E; Pasdar A; Kerachian MA
    Curr Probl Cancer; 2018 Nov; 42(6):572-581. PubMed ID: 29921458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
    Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
    Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripheral lung adenocarcinomas with KRAS mutations are more likely to invade visceral pleura.
    Raparia K; Villa C; Raj R; Cagle PT
    Arch Pathol Lab Med; 2015 Feb; 139(2):189-93. PubMed ID: 24694341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coaltered
    Datta J; Smith JJ; Chatila WK; McAuliffe JC; Kandoth C; Vakiani E; Frankel TL; Ganesh K; Wasserman I; Lipsyc-Sharf M; Guillem J; Nash GM; Paty PB; Weiser MR; Saltz LB; Berger MF; Jarnagin WR; Balachandran V; Kingham TP; Kemeny NE; Cercek A; Garcia-Aguilar J; Taylor BS; Viale A; Yaeger R; Solit DB; Schultz N; D'Angelica MI
    Clin Cancer Res; 2020 Mar; 26(5):1077-1085. PubMed ID: 31719050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple KRAS mutations in pancreatic adenocarcinoma: molecular features of neoplastic clones indicate the selection of divergent populations of tumor cells.
    Visani M; de Biase D; Baccarini P; Fabbri C; Polifemo AM; Zanini N; Pession A; Tallini G
    Int J Surg Pathol; 2013 Dec; 21(6):546-52. PubMed ID: 23426962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.